Lisata Therapeutics Announces First Patient Treated In The Second-Line Cholangiocarcinoma Cohort Of The BOLSTER Trial
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics has treated the first patient in the second-line cholangiocarcinoma cohort of the BOLSTER trial, following the successful enrollment in the first-line cohort.
September 17, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics has initiated treatment in the second-line cholangiocarcinoma cohort of the BOLSTER trial, indicating progress in their clinical trials for cancer therapies.
The initiation of treatment in the second-line CCA cohort suggests progress in Lisata's clinical trials, which could positively impact investor sentiment and the stock price. The successful completion of the first-line cohort enrollment further supports this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100